Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
881 stopped studies mapped to Malignant Intestinal Neoplasm and descendants · 90% state a reason
Over the 881 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03623464 | RCT of Mobile Apps & FitBit v. Usual Care | N/A | suspended | Aug 9, 2018 | Weill Medical College of Cornell University | Study is paused for interim analysis. | Efficacy / futility |
| NCT04973007 | Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of… | Phase 4 | terminated | Jul 22, 2021 | University of Colorado, Denver | Low Accrual | Enrollment / accrual |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 14, 2021 | Takeda | Sponsor decision based on limited anti-cancer activity of TAK-186. | Sponsor / business decision |
| NCT06882746 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon,… | Phase 1 | terminated | Mar 19, 2025 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT04031469 | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease | — | suspended | Jul 24, 2019 | ProgenaBiome | Administrative | Other (stated, no rule matched) |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | suspended | Nov 20, 2020 | Persephone Biosciences | Currently no funding to continue study. | Funding |
| NCT06039202 | CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects… | Phase 2 | suspended | Sep 15, 2023 | Holy Stone Healthcare Co., Ltd | Strategy under discussion | Sponsor / business decision |
| NCT03804255 | Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision… | — | withdrawn | Jan 15, 2019 | ECOG-ACRIN Cancer Research Group | Study closed before patients enrolled | Enrollment / accrual |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase 2 | suspended | Oct 1, 2019 | Thomas Jefferson University | Protocol is with FDA review, waiting for funding to be released | Funding |
| NCT07720115 | Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal… | Phase 2 | withdrawn | Jul 22, 2026 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT05930496 | Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III… | N/A | terminated | Jul 5, 2023 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT06487377 | IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced… | Phase 1 | withdrawn | Jul 5, 2024 | Shanghai Pudong Hospital | Study was stopped Sponsor discretion. No patients were dosed. | Other (stated, no rule matched) |
| NCT06929338 | xDRIVE in Metastatic Colorectal Cancer | — | withdrawn | Apr 16, 2025 | First Ascent Biomedical Inc. | Unable to finalize study agreements | Other (stated, no rule matched) |
| NCT06091930 | A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in… | Phase 1 | terminated | Oct 23, 2023 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT00642603 | A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy… | Phase 2 | terminated | Mar 25, 2008 | Hoffmann-La Roche | not stated | Not stated |
| NCT07388563 | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | Phase 1 | suspended | Feb 5, 2026 | National Cancer Institute (NCI) | New recruitment on hold for a protocol design amendment/modification. | Enrollment / accrual |
| NCT05497336 | A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated… | Phase 1 | terminated | Aug 11, 2022 | Innovent Biologics (Suzhou) Co. Ltd. | company development strategy adjustment | Sponsor / business decision |
| NCT07090174 | CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among… | Phase 2 | withdrawn | Jul 29, 2025 | University of California, San Diego | Study withdrawn prior to participant enrollment due to lack of study product. | Enrollment / accrual |
| NCT06221423 | Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer | — | withdrawn | Jan 24, 2024 | Fudan University | The study was withdrawn before participant enrollment because the research team decided not to… | Enrollment / accrual |
| NCT07057089 | Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced… | Phase 2 | suspended | Jul 9, 2025 | Hebei Medical University Fourth Hospital | Suspended due to lack of drug supply: the manufacturer ceased to provide investigational drug… | Drug supply |
| NCT03068403 | Dynamic Contrast Enhanced Ultrasound for Predict and Assess Rectal Cancer Response After…(RECT) | N/A | terminated | Mar 1, 2017 | University Hospital, Bordeaux | target number of inclusion not reached | Other (stated, no rule matched) |
| NCT03941366 | Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete… | N/A | terminated | May 7, 2019 | Henry Ford Health System | Lack of financial support | Funding |
| NCT05526079 | Watchful Waiting for Complete Responders to Therapy in Rectal Cancer | N/A | terminated | Sep 2, 2022 | Henry Ford Health System | Lack of financial support | Funding |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT07152821 | Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory,…(BATTMAN) | Phase 3 | terminated | Sep 3, 2025 | Canadian Cancer Trials Group | Pharmaceutical Sponsor discontinued trial financial support | Funding |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming… | Phase 1 | suspended | Jun 1, 2022 | David Wald | Drugs unavailable | Other (stated, no rule matched) |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | Phase 1 / Phase 2 | withdrawn | Apr 16, 2020 | Chongqing Precision Biotech Co., Ltd | The sponsor requested to terminate the study. | Other (stated, no rule matched) |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… | Phase 1 | terminated | Sep 5, 2024 | BeOne Medicines | The Sponsor has made the decision to terminate this study due to the lack of promising efficacy,… | Efficacy / futility |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 16, 2023 | Syndax Pharmaceuticals | Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in… | Efficacy / futility |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating… | Phase 2 | terminated | Jun 6, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With… | Phase 1 | suspended | Aug 1, 2023 | University of California, Davis | For internal interim analysis | Efficacy / futility |
| NCT06779669 | Use of Alternative and Complementary Medicine by Colorectal Cancer Patients(ALTERNATIVCCR) | N/A | terminated | Jan 16, 2025 | University Hospital, Limoges | Not enough awnser in the qualitative study | Other (stated, no rule matched) |
| NCT06692959 | A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal…(Neo-POLEM) | Phase 2 | terminated | Nov 18, 2024 | University of Southampton | funding withdrawal | Funding |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | terminated | Aug 24, 2022 | Day One Biopharmaceuticals, Inc. | Development discontinued. | Other (stated, no rule matched) |
| NCT01148056 | Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer | N/A | terminated | Jun 22, 2010 | Massachusetts General Hospital | The study was closed to enrollment due to slow accrual. | Enrollment / accrual |
| NCT05576896 | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the… | Phase 2 | terminated | Oct 13, 2022 | Northwestern University | The study was closed due to accrual. | Enrollment / accrual |
| NCT07292285 | The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.(SNOWW) | — | withdrawn | Dec 18, 2025 | University of Colorado, Denver | Sponsor decided not to move forward with the site. | Sponsor / business decision |
| NCT05331040 | Radiomics in Rectal Cancer | — | withdrawn | Apr 15, 2022 | NHS Grampian | Ill health of CI | Other (stated, no rule matched) |
| NCT07413510 | Precision Nursing vs Conventional Care in Laparoscopic Colorectal Cancer Surgery: A… | N/A | withdrawn | Feb 17, 2026 | Jiangsu Cancer Institute & Hospital | The trial was withdrawn before participant enrollment; no subjects were recruited and no data were… | Enrollment / accrual |
| NCT07152210 | Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the… | N/A | withdrawn | Sep 3, 2025 | Guangzhou Bio-gene Technology Co., Ltd | Due to corporate strategic adjustment. | Sponsor / business decision |
| NCT03745326 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor… | Phase 1 / Phase 2 | terminated | Nov 19, 2018 | National Cancer Institute (NCI) | Study was closed due to lack of accrual and study outcomes overlapped with another protocol's… | Enrollment / accrual |
| NCT05223036 | Testing Obeticholic Acid for Familial Adenomatous Polyposis | Phase 2 | terminated | Feb 3, 2022 | National Cancer Institute (NCI) | Protocol has been completed prematurely due to poor accrual and study feasibility. | Enrollment / accrual |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT03426371 | Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody… | Phase 3 | terminated | Feb 8, 2018 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Due to adjustments in our R\&D strategy, we are discontinuing the 140-III-01 study and initiating… | Sponsor / business decision |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | Phase 1 / Phase 2 | suspended | Jan 20, 2022 | University of Chicago | enrollment goal met pending determination of evaluable subjects | Enrollment / accrual |
| NCT06149741 | Defunctioning Left-sided Colostomy in Low Anterior Resection for Rectal Cancer(STOMALEFT) | N/A | terminated | Nov 29, 2023 | Umeå University | Logistical difficulties at study sites. 16/20 patients included. | Other (stated, no rule matched) |
| NCT05494658 | Impact of Preoperative Oral Branched-chain Amino Acids on Reducing Postoperative Insulin… | N/A | terminated | Aug 10, 2022 | Sun Peng | The mid-term analysis of the study showed no significant difference between the two groups. | Other (stated, no rule matched) |
| NCT06653010 | Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer(Wondercel-UWD1) | Early Phase 1 | suspended | Oct 22, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials